Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis
https://doi.org/10.4081/aiua.2021.1.1
Accepted: December 29, 2020
Supplementary Material: 131
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background: The Bacillus Calmette-Guerin (BCG) vaccine has long been used for the prevention of tuberculosis (TB) around the world. BCG is also used as an immunotherapy agent for the treatment of non-muscle invasive urinary bladder cancer. This scoping literature review and preliminary data analysis aims to summarize the literature correlating infantile BCG vaccination with the incidence of future bladder cancer.
Methods: Studies were identified by a formal literature search of MEDLINE and Cochrane Central Registrar of Controlled Trials following PRISMA guidelines. Preliminary data analysis was conducted on publicly accessible data summarizing the impact of gender, BCG vaccination, and socio-economic effects on crude and age-standardized rates of bladder cancer.
Results: As part of our analysis, preliminary regression models demonstrated BCG vaccination status, gender, and socio-economic status to have statistically significant effects on crude and age-standardized rates of bladder cancer incidence. BCG vaccination was associated with a 35-37% lower age-standardized rate of bladder cancer incidence.
Conclusions: There is very little literature examining the relationship between prior BCG vaccination and rates of bladder cancer incidence. Our limited data analysis indicates that a relationship does exist between infantile BCG vaccination and later bladder cancer development, although extensive future investigation is needed in this area.
Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: Morbidity and mortality of a worldwide epidemic. JAMA. 1995; 273:220-226. DOI: https://doi.org/10.1001/jama.1995.03520270054031
World Health Organization. Immunization, vaccines and biologicals: National programmes and systems. Retrieved (2020) from https://www.who.int/immunization/programmes_systems/en/#:~:text=The%20EPI%20launched%20at%20that,vaccine)%2C%20measles%20and%20poliomyelitis.
Keja K, Chan C, Hayden G, Henderson RH. Expanded programme on immunization. World Health Stat Q. 1988; 41:59-63.
World Health Organization. BCG vaccine: WHO position paper, February 2018-recommendations. Vaccine. 2018; 24:3408-3410. DOI: https://doi.org/10.1016/j.vaccine.2018.03.009
Faust L, Schreiber Y, Bocking N. A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities. BMC Public Health. 2019; 19:1504. DOI: https://doi.org/10.1186/s12889-019-7868-9
World Health Organization. Expanded programme on immunization (EPI) factsheet 2019: South-East Asia region.
Gillini L, Cooreman E, Wood T, et al. Global practices in regard to implementation of preventive measures for leprosy. PLoS Negl Trop Dis. 2017; 11:e0005399. DOI: https://doi.org/10.1371/journal.pntd.0005399
Taylor J, Becher E, Steinberg G. Update on the guideline of guidelines: Non muscle-invasive bladder cancer. BJUI. 2020; 125:197-205. DOI: https://doi.org/10.1111/bju.14915
Moss JT, Kadmon, D. BCG and the treatment of superficial bladder cancer. DICP. 1991; 25:1355-1367. DOI: https://doi.org/10.1177/106002809102501215
Chen S, Zhang N, Shao J, Wang X. Maintenance versus non-maintenance intravesical bacillus calmette-guerin installation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials. Intl JOS. 2018; 52:248-257.
Van Puffelen JH, Keating ST, Oosterwijk E, et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nature Rev Uro. 2020; 17:513-525. DOI: https://doi.org/10.1038/s41585-020-0346-4
World Cancer Research Fund. Worldwide cancer data: Global cancer statistics for the most common cancers. Retrieved 82018) from https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancerdata.
Richters A, Aben KH, Kiemeney LA. The global burden of urinary bladder cancer: An update. World J Urol. 2020; 38:1895-1904 DOI: https://doi.org/10.1007/s00345-019-02984-4
Usher NT, Chang S, Howard RS, et al. Association of BCG vaccination in childhood with subsequent cancer diagnoses: a 60-year follow-up of a clinical trial. JAMA Netw Open. 2019; 2:e1912014. DOI: https://doi.org/10.1001/jamanetworkopen.2019.12014
Daneshmand, Siamak. Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder. Retrieved (2020) from: https://www-uptodate-com.proxy.lib.nosm.ca/contents/epidemiologyand-risk-factors-of-urothelial-transitional-cell-carcinoma-of-the-bladder?search=bladder%20cancer%20epidemiology&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H4
Zwerling A, Behr M, Brewer T, et al. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practises. Retrieved (2011) from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062527/ DOI: https://doi.org/10.1371/journal.pmed.1001012
Morra ME, Kien ND, Elmaraezy A, et al. Early vaccination protects against childhood leukemia: A systematic review and meta-analysis. Sci Rep. 2017; 7:15986. DOI: https://doi.org/10.1038/s41598-017-16067-0
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
